Cargando…
MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology
Age-related increases in monoamine oxidase B (MAO-B) may contribute to neurodegeneration associated with Parkinson's disease (PD). The MAO-B inhibitor deprenyl, a long-standing antiparkinsonian therapy, is currently used clinically in concert with the dopamine precursor L-DOPA. Clinical studies...
Autores principales: | Mallajosyula, Jyothi K., Kaur, Deepinder, Chinta, Shankar J., Rajagopalan, Subramanian, Rane, Anand, Nicholls, David G., Di Monte, Donato A., Macarthur, Heather, Andersen, Julie K. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2229649/ https://www.ncbi.nlm.nih.gov/pubmed/18286173 http://dx.doi.org/10.1371/journal.pone.0001616 |
Ejemplares similares
-
Correction: MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology
por: Mallajosyula, Jyothi K., et al.
Publicado: (2012) -
Metabolic Control Analysis in a Cellular Model of Elevated MAO-B: Relevance to Parkinson’s Disease
por: Mallajosyula, Jyothi K., et al.
Publicado: (2009) -
Age-Related Behavioral Phenotype of an Astrocytic Monoamine Oxidase-B Transgenic Mouse Model of Parkinson’s Disease
por: Lieu, Christopher A., et al.
Publicado: (2013) -
Microdose lithium reduces cellular senescence in human astrocytes - a potential pharmacotherapy for COVID-19?
por: Viel, Tania, et al.
Publicado: (2020) -
A Possible Novel Anti-Inflammatory Mechanism for the Pharmacological Prolyl Hydroxylase Inhibitor 3,4-Dihydroxybenzoate: Implications for Use as a Therapeutic for Parkinson's Disease
por: Chinta, Shankar J., et al.
Publicado: (2012)